The struggle for energy in podocytes leads to nephrotic syndrome

Cell Cycle

Volumn 11, Issue 8, 2012, Pages 1504-1511

  Yan, Kunimasa ^a   Ito, Noriko ^a   Nakajo, Aya ^a   Kurayama, Ryota ^a   Fukuhara, Daisuke ^a   Nishibori, Yukino ^a   Kudo, Akihiko ^a   Akimoto, Yoshihiro ^a   Takenaka, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Everolimus; Mammalian target of rapamycin complex 1; Nutrient transporter; Puromycin aminonucleoside; Unfolded protein response

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID TRANSPORTER; EVEROLIMUS; GLUCOSE REGULATED PROTEIN 78; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; INITIATION FACTOR 2ALPHA; MESSENGER RNA; PROTEIN LAT3; PUROMYCIN AMINONUCLEOSIDE; UNCLASSIFIED DRUG;

CELL CYCLE PROGRESSION; CELL SURFACE; CELL SURVIVAL; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENERGY CONSUMPTION; ENERGY METABOLISM; ENZYME ACTIVATION; GENETIC TRANSCRIPTION AND TRANSLATION; GLOMERULUS CAPILLARY; HUMAN; NEPHROTIC SYNDROME; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; TRANSCYTOSIS; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

MAMMALIA; RATTUS;

EID: 84860329387     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.19825     Document Type: Review

References (92)

1. Nash MA, Edelman CM, Bernstein J, Barnett HL. The nephrotic syndrome. In: Pediatric Kidney Disease. Edited by Edelman CM, Boston, Little, Brown and Company 1992; 2:1247-66.
2. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008; 88:451-87; PMID:18391170; http://dx.doi.org/10.1152/physrev.00055.2006.
3. Tisher CC, Masden KM. Anatomy of the kidney. In: The kidney, edited by Brenner BM, Rector FC, Philadelphia, Saunders 1996; 5:3-71.
4. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006; 354:1387-401; PMID:16571882; http://dx.doi.org/10.1056/NEJMra052131.
5. Greka A, Mundel P. Cell Biology and Pathology of Podocytes. Annu Rev Physiol 2011; PMID:22054238.
6. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002; 57:189-95; PMID:12012382; http://dx.doi.org/10.1002/jemt.10072.
7. Griffin SV, Petermann AT, Durvasula RV, Shankland SJ. Podocyte proliferation and differentiation in glomerular disease: role of cell cycle regulatory proteins. Nephrol Dial Transplant 2003; 18:8-13; PMID:12953035; http://dx.doi.org/10.1093/ndt/gfg1069.
8. Nagata M, Yamaguchi Y, Ito K. Loss of mitotic activity and the expression of vimentin in glomerular epithelial cells of developing human kidneys. Anat Embryol (Berl) 1993; 187:275-9; PMID:8097081; http://dx.doi.org/10.1007/ BF00195765.
9. Rascle A, Suleiman H, Neumann T, Witzgall R. Role of transcription factors in podocytes. Nephron, Exp Nephrol 2007; 106:60-6; http://dx.doi.org/10. 1159/000101794.
10. Quaggin SE. Transcriptional regulation of podocyte specification and differentiation. Microsc Res Tech 2002; 57:208-11; PMID:12012385; http://dx.doi.org/10.1002/jemt.10076.
11. Kobayashi N, Gao SY, Chen J, Saito K, Miyawaki K, Li CY, et al. Process formation of the renal glomerular podocyte: is there common molecular machinery for processes of podocytes and neurons? Anat Sci Int 2004; 79:1-10; PMID:15088787; http://dx.doi.org/10.1111/j.1447-073x.2004.00066.x.
12. Matozaki T, Murata Y, Mori M, Kotani T, Okazawa H, Ohnishi H. Expression, localization and biological function of the R3 subtype of receptor-type protein tyrosine phosphatases in mammals. Cell Signal 2010; 22:1811-7; PMID:20633639; http://dx.doi.org/10.1016/j.cellsig.2010.07.001.
13. Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29:415-26; PMID:17955243; http://dx.doi.org/10.1007/s00281-007-0094-z.
14. Schönenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011; 26:18-24; PMID:20937691; http://dx.doi.org/10.1093/ndt/gfq617.
15. Chugh SS, Clement LC, Macé C. New Insights Into Human Minimal Change Disease: Lessons From Animal Models. Am J Kidney Dis 2011; PMID:21974967.
16. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010; 77:571-80; PMID:19924101; http://dx.doi.org/10.1038/ki.2009. 424.
17. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14:931-8; PMID:18724379; http://dx.doi.org/10.1038/nm.1857.
18. Hattori S, Kanda S, Harita Y. Tyrosine kinase signaling in kidney glomerular podocytes. J Signal Transduct 2011; 2011:317852; PMID:21776384; http://dx.doi.org/10.1155/2011/317852.
19. Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009; 111:9-15; PMID:19142027; http://dx.doi.org/10.1159/000191075.
20. st Century. Am J Physiol Endocrinol Metab 2010; 298:141-5; PMID:20009031; http://dx.doi.org/10.1152/ajpendo.00712.2009.
21. Coward RJ, Welsh GI, Yang J, Tasman C, Lennon R, Koziell A, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54:3095-102; PMID:16249431; http://dx.doi.org/10.2337/diabetes.54.11.3095.
22. Heilig C, Zaloga C, Lee M, Zhao X, Riser B, Brosius F, et al. Immunogold localization of high-affinity glucose transporter isoforms in normal rat kidney. Lab Invest 1995; 73:674-84; PMID:7474941.
23. Marcus RG, England R, Nguyen K, Charron MJ, Briggs JP, Brosius FC, 3rd. Altered renal expression of the insulin-responsive glucose transporter GLUT4 in experimental diabetes mellitus. Am J Physiol 1994; 267:816-24; PMID:7977785.
24. Schiffer M, Susztak K, Ranalletta M, Raff AC, Böttinger EP, Charron MJ. Localization of the GLUT8 glucose transporter in murine kidney and regulation in vivo in nondiabetic and diabetic conditions. Am J Physiol Renal Physiol 2005; 289:186-93; PMID:15741607; http://dx.doi.org/10.1152/ajprenal. 00234.2004.
25. Wang Y, Heilig K, Saunders T, Minto A, Deb DK, Chang A, et al. Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis. Am J Physiol Renal Physiol 2010; 299:99-111; PMID:20375117; http://dx.doi.org/10.1152/ajprenal.00466.2009.
26. Zhang H, Schin M, Saha J, Burke K, Holzman LB, Filipiak W, et al. Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2010; 299:91-8; PMID:20375116; http://dx.doi.org/10.1152/ajprenal.00021.2010.
27. McDaniel ML, Marshall CA, Pappan KL, Kwon G. Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic betacells. Diabetes 2002; 51:2877-85; PMID:12351422; http://dx.doi.org/10.2337/diabetes.51. 10.2877.
28. Blommaart EF, Luiken JJ, Meijer AJ. Autophagic proteolysis: control and specificity. Histochem J 1997; 29:365-85; PMID:9184851; http://dx.doi.org/10. 1023/A:1026486801018.
29. Patti ME, Brambilla E, Luzi L, Landaker EJ, Kahn CR. Bidirectional modulation of insulin action by amino acids. J Clin Invest 1998; 101:1519-29; PMID:9525995; http://dx.doi.org/10.1172/JCI1326.
30. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70:43-77; PMID:2404290.
31. Kadowaki M, Kanazawa T. Amino acids as regulators of proteolysis. J Nutr 2003; 133:2052-6; PMID:12771364.
32. Vary TC, Lynch CJ. Nutrient signaling components controlling protein synthesis in striated muscle. J Nutr 2007; 137:1835-43; PMID:17634251.
33. Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr 2006; 136:227-31; PMID:16365087.
34. Sekine Y, Nishibori Y, Akimoto Y, Kudo A, Ito N, Fukuhara D, et al. Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol 2009; 20:1586-96; PMID:19443642; http://dx.doi.org/10.1681/ASN. 2008070809.
35. Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, et al. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 2003; 278:43838-45; PMID:12930836; http://dx.doi.org/10.1074/jbc.M305221200.
36. Fukuhara D, Kanai Y, Chairoungdua A, Babu E, Bessho F, Kawano T, et al. Protein characterization of NA+-independent system L amino acid transporter 3 in mice: a potential role in supply of branched-chain amino acids under nutrient starvation. Am J Pathol 2007; 170:888-98; PMID:17322374; http://dx.doi.org/10. 2353/ajpath.2007.060428.
37. Kurayama R, Ito N, Nishibori Y, Fukuhara D, Akimoto Y, Higashihara E, et al. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest 2011; 91:992-1006; PMID:21403644; http://dx.doi.org/10.1038/labinvest.2011.43.
38. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447:728-34; PMID:12856181; http://dx.doi.org/10.1007/s00424-003-1107-y.
39. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447:735-43; PMID:12838422; http://dx.doi.org/10.1007/s00424-003-1103-2.
40. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004; 5:63-84; PMID:14965251; http://dx.doi.org/10.2174/1389200043489162.
41. Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside transporter proteins. Curr Vasc Pharmacol 2009; 7:426-34; PMID:19485885; http://dx.doi.org/10.2174/157016109789043892.
42. Podgorska M, Kocbuch K, Pawelczyk T. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 2005; 52:749-58; PMID:16265592.
43. Rodríguez-Mulero S, Errasti-Murugarren E, Ballarín J, Felipe A, Doucet A, Casado FJ, et al. Expression of concentrative nucleoside transporters SLC28 (CNT1-3) along the rat nephron: effect of diabetes. Kidney Int 2005; 68:665-72; PMID:16014043; http://dx.doi.org/10.1111/j.1523-755.2005. 00444.x.
44. Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol 2007; 18:2554-64; PMID:17687078; http://dx.doi.org/10.1681/ASN.2006070732.
45. Aymerich I, Foufelle F, Ferré P, Casado FJ, Pastor-Anglada M. Extracellular adenosine activates AMPdependent protein kinase (AMPK). J Cell Sci 2006; 119:1612-21; PMID:16569664; http://dx.doi.org/10.1242/jcs.02865.
46. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 2012; 52:381-400; PMID:22017684; http://dx.doi.org/10.1146/annurev-pharmtox-010611-134537.
47. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25:1895-908; PMID:21937710; http://dx.doi.org/10.1101/gad.17420111.
48. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307-18; PMID:19339977; http://dx.doi.org/10.1038/nrm2672.
49. Schröder M. Endoplasmic reticulum stress responses. Cell Mol Life Sci 2008; 65:862-94; PMID:18038217; http://dx.doi.org/10.1007/s00018-007-7383-5.
50. Anelli T, Sitia R. Protein quality control in the early secretory pathway. EMBO J 2008; 27:315-27; PMID:18216874; http://dx.doi.org/10.1038/sj. emboj.7601974.
51. Hegde RS, Ploegh HL. Quality and quantity control at the endoplasmic reticulum. Curr Opin Cell Biol 2010; 22:437-46; PMID:20570125; http://dx.doi.org/10.1016/j.ceb.2010.05.005.
52. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007; 581:3641-51; PMID:17481612; http://dx.doi.org/10.1016/j.febslet. 2007.04.045.
53. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002; 110:1389-98; PMID:12438434.
54. Cybulsky AV. Endoplasmic reticulum stress in proteinuric kidney disease. Kidney Int 2010; 77:187-93; PMID:19812538; http://dx.doi.org/10.1038/ki.2009. 389.
55. Dickhout JG, Krepinsky JC. Endoplasmic reticulum stress and renal disease. Antioxid Redox Signal 2009; 11:2341-52; PMID:19508129; http://dx.doi.org/10.1089/ars.2009.2705.
56. Cybulsky AV, Takano T, Papillon J, Khadir A, Liu J, Peng H. Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem 2002; 277:41342-51; PMID:12191998; http://dx.doi.org/10.1074/jbc.M204694200.
57. Cybulsky AV, Takano T, Papillon J, Bijian K. Role of the endoplasmic reticulum unfolded protein response in glomerular epithelial cell injury. J Biol Chem 2005; 280:24396-403; PMID:15863508; http://dx.doi.org/10.1074/jbc. M500729200.
58. Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434:181-8; PMID:21309747; http://dx.doi.org/10.1042/BJ20101569.
59. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature 1988; 332:462-4; PMID:3352747; http://dx.doi.org/10.1038/332462a0.
60. Inagi R, Nangaku M, Usuda N, Shimizu A, Onogi H, Izuhara Y, et al. Novel serpinopathy in rat kidney and pancreas induced by overexpression of megsin. J Am Soc Nephrol 2005; 16:1339-49; PMID:15788472; http://dx.doi.org/10.1681/ASN. 2004070600.
61. Inagi R, Nangaku M, Onogi H, Ueyama H, Kitao Y, Nakazato K, et al. Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excessive protein accumulation. Kidney Int 2005; 68:2639-50; PMID:16316340; http://dx.doi.org/10.1111/j.1523-755.2005.00736.x.
62. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 2009; 296:213-29; PMID:18784259; http://dx.doi.org/10. 1152/ajprenal.90421.2008.
63. Ito N, Nishibori Y, Ito Y, Takagi H, Akimoto Y, Kudo A, et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest 2011; 91:1584-95; PMID:21876538; http://dx.doi.org/10.1038/labinvest.2011.135.
64. Yan K, Khoshnoodi J, Ruotsalainen V, Tryggvason K. N-linked glycosylation is critical for the plasma membrane localization of nephrin. J Am Soc Nephrol 2002; 13:1385-9; PMID:11961028; http://dx.doi.org/10.1097/01.ASN.0000013297. 11876.5B.
65. Fujii Y, Khoshnoodi J, Takenaka H, Hosoyamada M, Nakajo A, Bessho F, et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006; 69:1350-9; PMID:16531978.
66. Williams DB. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 2006; 119:615-23; PMID:16467570; http://dx.doi.org/10.1242/jcs.02856.
67. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8:519-29; PMID:17565364; http://dx.doi.org/10.1038/nrm2199.
68. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4:966-77; PMID:15573118; http://dx.doi.org/10.1038/nrc1505.
69. Abraham RT. TOR signaling: an odyssey from cellular stress to the cell growth machinery. Curr Biol 2005; 15:139-41; PMID:15723787; http://dx.doi.org/ 10.1016/j.cub.2005.02.015.
70. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151-71; PMID:15094765; http://dx.doi.org/10. 1038/sj.onc.1207542.
71. Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008; 29:541-51; PMID:18342602; http://dx.doi.org/10.1016/j.molcel.2007.12.023.
72. Klümpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. Oncologist 2010; 15:1262-9; PMID:21147869; http://dx.doi.org/10.1634/ theoncologist.2010-0196.
73. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11:1845-57; PMID:12457444; http://dx.doi.org/10.1517/ 13543784.11.12.1845.
74. Ramaiah A, Hathaway JA, Atkinson DE. Adenylate as a metabolic regulator. Effect on yeast phosphofructokinase kinetics. J Biol Chem 1964; 239:3619-22; PMID:14257585.
75. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 2001; 23:1112-9; PMID:11746230; http://dx.doi.org/10.1002/bies.10009.
76. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al.; Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233-42; PMID:19155978; http://dx.doi.org/10.1097/TP.0b013e3181927a41.
77. Torras J, Herrero-Fresneda I, Gulias O, Flaquer M, Vidal A, Cruzado JM, et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24:3632-40; PMID:19671594; http://dx.doi.org/10.1093/ndt/gfp367.
78. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113:1390-7; PMID:15146236.
79. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3:169-76; PMID:12563300; http://dx.doi.org/10.1038/nri1004.
80. Carpenter S, O'Neill LA. Recent insights into the structure of Toll-like receptors and posttranslational modifications of their associated signalling proteins. Biochem J 2009; 422:1-10; PMID:19627256; http://dx.doi.org/10.1042/ BJ20090616.
81. Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, et al. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest 2005; 115:1188-98; PMID:15841212.
82. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 2011; 11:201-12; PMID:21331080; http://dx.doi.org/10.1038/nri2938.
83. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783:673-94; PMID:18302942; http://dx.doi.org/10.1016/j.bbamcr.2008.01.024.
84. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86:901-40; PMID:16816141; http://dx.doi.org/10.1152/physrev. 00031.2005.
85. Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol 2005; 167:315-25; PMID:16049319; http://dx.doi.org/10.1016/S0002- 9440(10)62977-X.
86. Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75:1-12; PMID:19818358; http://dx.doi.org/10.1016/j.steroids.2009.09.002.
87. Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB. Glucocorticoid receptor physiology. Rev Endocr Metab Disord 2007; 8:321-30; PMID:18049904; http://dx.doi.org/10.1007/s11154-007-9059-8.
88. Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, et al. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int 1999; 56:65-73; PMID:10411680; http://dx.doi.org/10.1046/ j.1523-755.1999.00503.x.
89. Kataoka S, Kudo A, Hirano H, Kawakami H, Kawano T, Higashihara E, et al. 11beta-hydroxysteroid dehydrogenase type 2 is expressed in the human kidney glomerulus. J Clin Endocrinol Metab 2002; 87:877-82; PMID:11836336; http://dx.doi.org/10.1210/jc.87.2.877.
90. Takemoto M, He L, Norlin J, Patrakka J, Xiao Z, Petrova T, et al. Large-scale identification of genes implicated in kidney glomerulus development and function. EMBO J 2006; 25:1160-74; PMID:16498405; http://dx.doi.org/10.1038/ sj.emboj.7601014.
91. Nishibori Y, Katayama K, Parikka M, Oddsson A, Nukui M, Hultenby K, et al. Glcci1 deficiency leads to proteinuria. J Am Soc Nephrol 2011; 22:2037-46; PMID:21949092; http://dx.doi.org/10.1681/ASN.2010111147.
92. Chapman MS, Askew DJ, Kuscuoglu U, Miesfeld RL. Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Mol Endocrinol 1996; 10:967-78; PMID:8843413; http://dx.doi.org/10.1210/me.10.8.967.